How Patient Education Improves Clinical Trial Enrollment and Retention

By: David Grew MD MPH

"Patient education is not just a recruitment tool. It is also a retention tool."

∗ ∗ ∗

Clinical trials cannot succeed if eligible patients never enroll or if participants drop out before the study is complete. That makes enrollment and retention two of the biggest practical challenges in clinical research. Reviews of the field consistently identify patient-level barriers such as limited understanding, fear, mistrust, logistical burden, and difficulty navigating trial information.

That is where patient education matters.

Good patient education does not guarantee enrollment. It also should not pressure anyone into joining a study. But it can make clinical trials easier to understand, easier to navigate, and easier to stay engaged with over time. FDA and NIH sources emphasize that informed consent and trial communication should be understandable, use plain language, and facilitate real understanding rather than simply produce a signature.

Why patients often do not enroll

Many patients never reach a true decision point because they do not fully understand what a clinical trial is, how it compares with standard care, or what participation would involve. Research and policy reviews describe lack of patient education, confusing language, and communication barriers as real obstacles to recruitment.

This is especially important in cancer care, where patients are often processing a new diagnosis, complicated treatment options, emotional stress, and time pressure all at once. If trial information is dense, abstract, or full of jargon, many patients may disengage before they can make an informed choice. FDA has specifically pushed for clearer, more concise, more patient-friendly consent communication for this reason.

Education improves understanding

At its core, patient education helps people answer practical questions such as:

• What is this trial studying?
• Why might it be relevant to me?
• What treatments are involved?
• What are the risks, benefits, and uncertainties?
• How many visits, tests, and time commitments are required?

When those basics are explained clearly, patients are better able to decide whether a trial fits their goals and values. FDA guidance describes informed consent as a process that should facilitate understanding from recruitment through the end of the study, not just a document to sign.

Better understanding does not just support ethics. It also supports operations. When patients know what they are agreeing to, there is less room for surprise, confusion, or avoidable dropout later.

Education can support enrollment

Educational materials can improve enrollment by reducing fear of the unknown and making trial participation feel more concrete. A published study of an educational video for breast cancer patients found improved attitudes related to clinical trial participation after the intervention, suggesting that clearer education can positively affect willingness to consider a study.

This does not mean every brochure or video will raise accrual on its own. But it does suggest that communication format matters. Reviews on health literacy and informed consent similarly note that understanding trial information is a major part of whether patients feel able to participate.

Education can also support retention

Enrollment is only the beginning. Once a patient joins a study, they still need to understand schedules, procedures, side effects, reporting expectations, and the importance of staying connected with the study team.

Retention research shows that dropout can be driven by burden, confusion, unmet expectations, and poor communication. Reviews of participant retention highlight that keeping people in trials requires clear ongoing communication and support, not just a successful initial consent discussion.

In other words, education is not just a recruitment tool. It is also a retention tool.

Patients are more likely to stay engaged when they understand:

• why visits matter
• what side effects to expect
• when to call the team
• what the study timeline looks like
• and how their participation contributes to the research question

Why plain language matters

One of the clearest lessons from regulators and patient advocates is that plain language matters. The FDA has published patient-friendly language resources for cancer clinical trials and has publicly emphasized making informed consent easier to understand. The goal is not to “dumb down” trial information. The goal is to make it usable.

Patients cannot make informed decisions if the words themselves are the barrier.

Terms like randomization, progression-free survival, placebo, screening failure, or biomarker-driven eligibility may be familiar to research professionals but unclear to many patients. Educational content that translates those ideas into everyday language can reduce unnecessary confusion and improve confidence.

Education is more than the consent form

A common mistake is treating patient education as identical to the consent document. But effective education usually starts before consent and continues after enrollment. FDA training materials explicitly describe informed consent as a process that begins with recruitment materials and continues through the study.

That means education may include:

• referral-facing materials
• short videos
• FAQs
• plain-language web pages
• visit preparation content
• reminder materials
• side-effect education
• study calendars and next-step guides

These tools can help patients understand not only the trial’s purpose, but also what participation will feel like in real life.

Education helps sites too

Patient education does not only help patients. It can also reduce strain on site teams.

When patients arrive with a clearer grasp of the study, coordinators and investigators may spend less time correcting basic misunderstandings and more time answering meaningful personal questions. Better baseline understanding can make consent discussions more efficient and help align expectations earlier. Reviews on recruitment and retention repeatedly point to communication quality and participant burden as major operational issues.

That can matter for both enrollment and retention, especially in trials that are complex or time-intensive.

What good patient education looks like

Strong patient education for clinical trials is usually:

• clear rather than jargon-heavy
• honest about risks and uncertainty
• specific about logistics and expectations
• accessible in language and format
• ongoing, not just delivered once
• patient-centered, meaning it answers the questions patients actually have

The purpose is not persuasion. The purpose is understanding. High-quality informed consent and education should leave patients with a full and clear sense of the study’s risks, benefits, commitments, and burdens.

–

Clinical trial enrollment and retention problems are often described as operational problems. But many of them are also communication problems.

When trial information is easier to understand, patients are better able to consider participation, prepare for what lies ahead, and stay engaged throughout the study. Clear patient education cannot solve every barrier, but it can address one of the most fixable ones: confusion.

For sponsors, sites, and care teams, that makes patient education more than a nice extra. It is part of how better trials get done.

–

To learn more, browse our library of clinical trial topics.

Hire PRIMR to create custom video content for your clinical trial or medical product today.

‍
FAQs:

‍

Can patient education guarantee better clinical trial enrollment?

No. Enrollment depends on many factors, including eligibility, site access, physician referral patterns, logistics, and patient preferences. But better education can reduce confusion and help patients make more informed decisions about whether a trial is right for them. If you are considering a study, ask your care team to explain it in plain language and compare it with your standard treatment options.

Does patient education only matter before a patient joins a trial?

No. Education also matters after enrollment. Ongoing explanations about schedules, side effects, study goals, and follow-up expectations can help patients stay engaged and reduce avoidable dropout. If you are already on a trial and something feels unclear, contact your study team rather than guessing.

Should patient education be separate from the consent form?

Yes, often. The consent form is important, but by itself it may not be the easiest way for patients to learn. FDA materials emphasize that informed consent is a process, not just a document, and that information should be understandable. Patients should ask for explanations, visuals, or simpler summaries if the written form feels overwhelming.

Can plain-language materials still be accurate enough for clinical trials?

Yes. Clear language and scientific accuracy are not opposites. The FDA has specifically encouraged patient-friendly language in cancer clinical trials so patients can better understand difficult terms. If a trial explanation feels too technical, ask your care team to restate it in simpler language.

Can better education help with retention, not just recruitment?

Yes. Retention research shows that communication, expectations, and participant burden all affect whether patients stay in a study. Good education can help patients understand what is coming and why it matters, which may make participation easier to sustain. If trial demands are becoming hard to manage, contact your care team early rather than waiting until you feel overwhelmed.

‍